Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30.

Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

Author information

1
Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, USA.
2
Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
3
Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA.
4
Blood and Marrow Transplantation Program, Washington University, St Louis, MO, USA.
5
Sutter East Bay Medical Foundation, Berkeley, CA, USA.
6
Department of Cardiology, University of Michigan, Ann Arbor, MI, USA.
7
Hematology-Oncology, Mie University Hospital, Mie, Japan.
8
Pediatric Hematology Oncology, Indiana University, Indianapolis, IN, USA.
9
Blood and Marrow Transplantation Program, Columbia University, New York, NY, USA.
10
Department of Medicine, University of Colorado, Aurora, CO, USA; Department of Medicine, University Medical Center Nijmegen, Netherlands.
11
Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI, USA. Electronic address: reddypr@umich.edu.

Abstract

BACKGROUND:

Acute graft-versus-host disease (GVHD) remains a barrier to more widespread application of allogeneic haemopoietic stem-cell transplantation. Vorinostat is an inhibitor of histone deacetylases and was shown to attenuate GVHD in preclinical models. We aimed to study the safety and activity of vorinostat, in combination with standard immunoprophylaxis, for prevention of GVHD in patients undergoing related-donor reduced-intensity conditioning haemopoietic stem-cell transplantation.

METHODS:

Between March 31, 2009, and Feb 8, 2013, we did a prospective, single-arm, phase 1/2 study at two centres in the USA. We recruited adults (aged ≥18 years) with high-risk haematological malignant diseases who were candidates for reduced-intensity conditioning haemopoietic stem-cell transplantation and had an available 8/8 or 7/8 HLA-matched related donor. All patients received a conditioning regimen of fludarabine (40 mg/m(2) daily for 4 days) and busulfan (3.2 mg/kg daily for 2 days) and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28) and tacrolimus (0.03 mg/kg a day, titrated to a goal level of 8-12 ng/mL, starting day -3 until day 180). Vorinostat (either 100 mg or 200 mg, twice a day) was initiated 10 days before haemopoietic stem-cell transplantation until day 100. The primary endpoint was the cumulative incidence of grade 2-4 acute GVHD by day 100. This trial is registered with ClinicalTrials.gov, number NCT00810602.

FINDINGS:

50 patients were assessable for both toxic effects and response; eight additional patients were included in the analysis of toxic effects. All patients engrafted neutrophils and platelets at expected times after haemopoietic stem-cell transplantation. The cumulative incidence of grade 2-4 acute GVHD by day 100 was 22% (95% CI 13-36). The most common non-haematological adverse events included electrolyte disturbances (n=15), hyperglycaemia (11), infections (six), mucositis (four), and increased activity of liver enzymes (three). Non-symptomatic thrombocytopenia after engraftment was the most common haematological grade 3-4 adverse event (nine) but was transient and all cases resolved swiftly.

INTERPRETATION:

Administration of vorinostat in combination with standard GVHD prophylaxis after related-donor reduced-intensity conditioning haemopoietic stem-cell transplantation is safe and is associated with a lower than expected incidence of severe acute GVHD. Future studies are needed to assess the effect of vorinostat for prevention of GVHD in broader settings of haemopoietic stem-cell transplantation.

FUNDING:

Merck, Leukemia and Lymphoma Society, National Institutes of Health, St Baldrick's Foundation, Michigan Institute for Clinical and Health Research.

PMID:
24295572
PMCID:
PMC4103793
DOI:
10.1016/S1470-2045(13)70512-6
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center